Logotype for Mayne Pharma Group Limited

Mayne Pharma Group (MYX) AGM 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Mayne Pharma Group Limited

AGM 2026 summary

19 Nov, 2026

Opening remarks and agenda

  • Agenda: Chair’s Address, Business Update, Formal Business and Close; Professor Bruce Robinson chaired, with CEO Aaron Gray leading the business update.

Financial performance review

  • FY26 revenue was A$383.7m, down 6% YoY; gross margin rose 4.1 percentage points to 64.7%, while underlying EBITDA fell 27% to A$34.2m.

  • FY26 direct segment contribution was A$107.1m, down 2%; adjusted operating cash flow from continuing operations was A$34.5m, down 24%; cash and marketable securities were A$80.0m at 30 June 2026.

  • Branded products rose to 83% of FY26 net sales from 79% in FY25, alongside gross margin expansion to 65% from 61%.

  • 1Q FY27 revenue was A$95.7m, down 2% YoY; gross margin was 63%, underlying EBITDA A$5.3m, down 52%, and direct segment contribution A$23.3m, down 23%.

  • 1Q FY27 Women’s Health revenue was US$34.4m, up 9% YoY, while Dermatology/DistributeRx revenue was US$18.9m, down 16%; respective direct contributions were US$12.8m and US$3.1m.

Board and executive committee updates

  • Directors and KMP listed: Chair Professor Bruce Robinson; CEO Aaron Gray; CFO Griffin Buchanan; and Non-Executive Directors Ann Custin, David Petrie, Meghan Rivera and Jacob Ma-Weaver.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Mayne Pharma Group